Lumipulse G β-Amyloid Ratio (1-42/1-40)

About H.U. Group Holdings

H.U. Group Holdings is a leading integrated healthcare company in Japan, with a core business in clinical laboratory testing and the development, manufacturing, and sale of in-vitro diagnostics. Its strategic subsidiaries, SRL and Fujirebio, provide a comprehensive portfolio from routine testing to advanced cancer diagnostics and companion diagnostics. The company leverages its dual strength in testing services and IVD manufacturing to drive growth in precision medicine and global diagnostics markets.

Therapeutic Areas

Other Alzheimer's Disease Diagnosis Drugs